This week's roundup of Houston innovators includes Ayse McCracken of Ignite Healthcare Network, Paul Cherukuri of Rice University, and Oyetewa Oyerinde of Baylor College of Medicine. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health care to academia — recently making headlines in Houston innovation.

Ayse McCracken, founder of Ignite Healthcare Network

Ayse McCracken, founder of Ignite Healthcare Network, joins the Houston Innovators Podcast to discuss how she's growing her impact on female health tech founders. Photo via LinkedIn

With a decades-long career in health care, Ayse McCracken's most recent professional chapter has been laser focused on finding, supporting, and accelerating female-founded startups in health tech with her nonprofit, Ignite Healthcare Network.

Originally founded in 2017 as a pitch competition, Ignite has evolved to become an active and integral program for female health tech entrepreneurs. Ninety-one founders have graduated from Ignite and gone on to raise over $550 million in funding for their ventures. Currently, Ignite has 19 women in its 2023 cohort, which concludes November 9 with the annual Fire Pitch competition.

"Having an impact in the health care industry and finding solutions is important to me," McCracken says of her passion for Ignite on this week's episode of the Houston Innovators Podcast. "The second aspect of that is there are so many women in health care, and yet you don't see them in leadership roles." Read more.

Paul Cherukuri, vice president of innovation at Rice University

Paul Cherukuri, vice president of innovation at Rice University, has had a busy week. Photo via Rice.edu

If it's seemed like a lot has been happening on Rice University campus this month, it's because it has. This week, Paul Cherukuri, Rice’s vice president for innovation hosted an event announcing the university's Biotech Launch Pad, a new accelerator focused on commercializing health care innovations.

“The Biotech Launch Pad is the first in a series of Rice Moonshots that are hyper-focused on building a ‘speed and scale’ innovation ecosystem across Houston," Cherukuri says. "We at Rice are committed towards driving the Biotech Launch Pad in collaboration with our partners within the Texas Medical Center and the new Helix Park campus.” Read more.

The university also recently announced:

  • The Rice University Office of Innovation's newly established the One Small Step Grant program that will provide funding to faculty working on "promising projects with commercial potential." Read more.
  • The opening of the Ralph S. O’Connor Building for Engineering and Science, the university's largest core campus research facility. The 250,000-square-foot building is the new home for four key research areas at Rice: advanced materials, quantum science and computing, urban research and innovation, and the energy transition. The university aims for the space to foster collaboration and innovation between the disciplines. Read more.

Oyetewa Oyerinde, leader of the Skin of Color Clinic and assistant professor of dermatology at Baylor College of Medicine

The Skin of Color Clinic is devoted to the unique needs of patients of all ethnicities. Photo courtesy of BCM

All skin is created equal, but not all skin behaves the same. It’s with this in mind that Baylor Medicine Dermatology has announced the debut of its newest office.

The Skin of Color Clinic is located inside the Jamail Specialty Care Center and is devoted to the unique needs of patients of all ethnicities.

The leader of the Skin of Color Clinic is assistant professor of dermatology, Oyetewa Oyerinde. Dr. Oyerinde, a Howard University and University of Illinois at Chicago College of Medicine alum, completed her residency training at Harvard University, where she made it to the role of chief resident in her final year.

“I am excited to lead a clinic that addresses skin issues commonly found in underserved populations,” Oyerinde says in a news release. “I want people in Houston to know that there is a place where an expert will know how to care for their specific needs.” Read more.

Ignite Healthcare Network has hosted a pitch compeition for a few years now, but this is the first year for its mini-accelerator program. Courtesy of Ignite

Houston nonprofit launches accelerator program to give women-led startup a leg up within health care

The future is female

Within health care, female consumers make 80 percent of the buying power while women hold 65 percent of the workforce's jobs, according to a recent study. However, when you look at the C-suites in the industry, those percentages fall drastically, says Ayse McCracken.

"For as many women as there are involved in health care, it's not reflected in leadership," says McCracken, founder of Ignite Healthcare Network. "That's what brought us together."

Just 30 percent of health care C-suites are women — and only 13 percent have female CEOs, per the report by Oliver Wyman. Houston-based nonprofit Ignite is an organization comprised of over 150 of these rare female health care execs and focused on clearing a path for future female leaders in the industry.

McCracken founded the network in 2016, and her team established a "Shark Tank-style" pitch competition. After three years of the annual event seeing successes, Ignite is introducing its inaugural mini-accelerator program.

"As we saw this innovation economy and startup space begin to evolve in the city, it seemed that our contribution to this was that we could help incubate and find companies that had high likelihood of success," says McCracken.

Ignite and its partners identified 13 female-led companies from all around the world were selected from over 80 applications and now will go through a 10-week program called the Customer-Partner Program. Each company is paired with a partner and potential customer — from Memorial Hermann and Texas Children's Hospital to Humana and Gallagher.

Here are the participating female-led startups:

  • iTreatMD from San Francisco
  • BabyNoggin (by Qidza) from San Francisco
  • Ria Health from San Francisco
  • Savonix from San Francisco
  • MotiSpark from Los Angeles
  • UpHold Health from Chicago
  • Sound Scouts from Sydney, Australia
  • Augment Therapy from Cleveland, Ohio
  • Oncora Medical Philadelphia
  • Materna Medical from Mountain View, California
  • Path Ex Inc Houston
  • PyrAmes Inc. from Cupertino, California
  • Spoke Health Denver

The Fire Pitch Competition will take place on October 17 at the Texas Medical Center's Innovation Institute. Hundreds of thousands of dollars in prizes is on the line for the 13 companies.

"This year's event is already receiving increased recognition from investors," says Ignite board member and event co-chair, Cheryl Stavins, in a release. "In addition to the top three finalists sharing awards that include entry into the TMCx Digital Health Accelerator, over $125,000 in professional services, and cash prizes of $10,000, Fire Pitch participants will be eligible for investment prizes."

The Texas Halo Fund will be awarding its $100,000 investment prize, called the Corona Award, along with a $50,000 prize from TMC Innovation Institute.

Beyond the new program, McCracken says she wants to expand Ignite's reach and capabilities for its members and startups — including new investment opportunities.

"I think what we're doing now is reaching out beyond Houston and looking at how we can continue to grow the opportunity to have an impact and help women-led companies and women in organizations," she says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.